Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 247

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Johnson, K P, Brooks, B R, Ford, C C, Goodman, A, Guarnaccia, J, Lisak, R P, Myers, L W, Panitch, H S, Pruitt, A, Rose, J W, Kachuck, N, Wolinsky, J S, Copolymer 1 Multiple Sclerosis Study Group · 2000 · Multiple Sclerosis Journal

Abstract

In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for patients with relapsing-remitting multiple sclerosis. Of the original 251 patients randomized to receive glatiramer acetate or placebo, 208 chose to continue in an open-label study with all patients receiving active drug. The majority of the original double-blind cohort continues to receive glatiramer acetate by daily subcutaneous injection and are evaluated at 6-month intervals and during suspected relapse. The data reported here are from approximately 6 years of organized evaluation, including the double-blind phase of up to 35 months and the open-label phase of over 36 months. Daily subcutaneous injections of 20 mg glatiramer acetate were well tolerated. The mean annual relapse rate of the patients who received glatiramer acetate since randomization and continued into the open-label study was 0.42 (95% confidence interval (CI), CI=0.34-0.51). The rate per year has continued to drop and for the sixth year is 0.23. Of the group who have received glatiramer acetate without interruption for 5 or more years, 69.3% were neurologically unchanged or have improved from baseline by at least one step on the Expanded Disability Status Scale (EDSS). Patients who left the open-label phase were surveyed by questionnaire. The majority responded, providing information about their current status and reasons for dropping out. This study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and in slowing the accumulation of disability in patients with relapsing forms of multiple sclerosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/135245850000600407

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 247

Metadata

Authors
Johnson, K. P., Brooks, B. R., Ford, C. C., Goodman, A., Guarnaccia, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Pruitt, A., Rose, J. W., Kachuck, N., Wolinsky, J. S., & Copolymer 1 Multiple Sclerosis Study Group
Venue
Multiple Sclerosis Journal
Published
2000-08
Volume
6
Issue
4
Pages
255-266
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2984556666
Cited by
247
References
1
FWCI
14.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. https://app.cochat.ai/papers/10.1177/135245850000600407
The paper
Johnson, K. P., Brooks, B. R., Ford, C. C., Goodman, A., Guarnaccia, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Pruitt, A., Rose, J. W., Kachuck, N., Wolinsky, J. S., & Copolymer 1 Multiple Sclerosis Study Group. (2000). Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis Journal. https://doi.org/10.1177/135245850000600407

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.